Gilead Sciences Inc - $GILD STOCK NEWS

Kite, a Gilead Company, and Arcellx, Inc. announced operational updates on their anito-cel multiple myeloma program. They shared the iMMagine-3 trial design, manufacturing details, and plans to present data from the iMMagine-1 trial. Anito-cel is a BCMA CAR T cell therapy for relapsed/refractory multiple myeloma.

Gilead's FOCUS Program, launched in 2010, has been instrumental in early HIV detection and linkage to care. By partnering with state and local officials, healthcare providers, and organizations, the program has significantly reduced late-stage HIV diagnoses in underserved populations across the United States.

Gilead's partnership with the government of Mauritius has helped in the elimination of Hepatitis C in the country. By providing low-cost treatment and working with high-prevalence regions, the company has contributed to the success of patients like James, who is now free from the disease. The government's commitment and public-private partnerships have been instrumental in the progress towards eradicating Hepatitis C in the region.

Gilead Sciences, Inc. and Kite, a Gilead Company, will present 18 abstracts at the 2024 ASCO Annual Meeting, showcasing their commitment to developing innovative cancer treatments. The data cover a broad range of cancers, including lung, breast, and gastrointestinal, with highlights on Trodelvy in NSCLC, gastrointestinal pipeline progress, and new CAR T-cell therapy data. The company continues to focus on transforming cancer treatment through groundbreaking research.

Forbes has recognized Gilead as one of America's Best Employers for Diversity. The company's commitment to inclusion and diversity is highlighted, reflecting positive feedback from employees and the community. Gilead Sciences, a biopharmaceutical company, aims to innovate medicines for unmet medical needs globally.

Gilead Sciences, Inc. (Nasdaq: GILD) executives will be speaking at several upcoming investor conferences, showcasing the company's commitment to advancing innovative medicines for life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. The live webcasts and replays will be available on the company's investors page. Gilead operates globally with headquarters in Foster City, California.

Gilead Sciences announced the FDA approval of an updated label for Biktarvy, a treatment for pregnant people with HIV-1. The label includes additional data from Study 5310, supporting the safety and efficacy of Biktarvy in pregnant individuals with suppressed viral loads. Biktarvy is recognized as an alternative regimen for use during pregnancy and for those trying to conceive, with guidelines recommending its continuation for virologically suppressed individuals who may become pregnant. The label update signifies a significant milestone in HIV treatment research, providing assurance for people of childbearing potential to remain on Biktarvy if pregnant.

Gilead Sciences announced strong first quarter 2024 financial results with a 6% increase in product sales excluding Veklury, totaling $6.1 billion. Biktarvy sales rose by 10% to $2.9 billion, and Oncology sales increased by 18% to $789 million. The CymaBay acquisition led to a $3.9 billion charge impacting diluted EPS. Gilead's total revenue increased by 5% to $6.7 billion, with a significant decrease in diluted EPS due to acquisition-related charges. The company had $4.7 billion in cash as of March 31, 2024.

Gilead Sciences recently published its 2023 Environmental, Social, and Governance (ESG) Impact Report, showcasing its achievements in innovating scientific solutions, advancing health equity, empowering communities, and sustaining the planet. The report highlights Gilead's commitment to creating a healthier world while benefiting people, communities, and the environment.